Bestatin inhibits the development of cutaneous melanoma by inhibiting the expression of LTA4H
Pan Luo, Mingyi Yang, Yani Su, Pengfei Wen, Xiqin Lu · 2026
Read Bestatin inhibits the development of cutaneous melanoma by inhibiting the expression of LTA4H by Pan Luo, Mingyi Yang, Yani Su, Pengfei Wen, Xiqin Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13457203.txt.
Description
Pan Luo and colleagues hunt for new drug targets in cutaneous melanoma, the skin cancer behind most skin-cancer deaths, using human genetics before moving to the lab bench. Their 2026 study applies Mendelian randomization, a method that uses inherited gene variants as natural experiments, to expression data for 2,664 drug-target genes and genome data from the UK Biobank and FinnGen. One gene stood out: LTA4H, whose higher activity appeared to drive melanoma growth.
Cell experiments backed the genetic signal. Melanoma lines carried more LTA4H than normal fibroblasts, dialing the gene down in SK-MEL-28 cells weakened their growth, movement, and invasion, while raising it in A-375 cells did the opposite. Bestatin, an existing drug that targets this pathway, curbed the malignant behavior of A-375 cells by lowering LTA4H. The authors present LTA4H as a fresh target and bestatin as a repurposing candidate worth further testing.
Catalog record
| CREATOR | Pan Luo, Mingyi Yang, Yani Su, Pengfei Wen, Xiqin Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |